Rinath Jeselsohn

6.2k total citations · 2 hit papers
74 papers, 2.1k citations indexed

About

Rinath Jeselsohn is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Rinath Jeselsohn has authored 74 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 39 papers in Oncology and 28 papers in Molecular Biology. Recurrent topics in Rinath Jeselsohn's work include Advanced Breast Cancer Therapies (36 papers), Estrogen and related hormone effects (24 papers) and HER2/EGFR in Cancer Research (18 papers). Rinath Jeselsohn is often cited by papers focused on Advanced Breast Cancer Therapies (36 papers), Estrogen and related hormone effects (24 papers) and HER2/EGFR in Cancer Research (18 papers). Rinath Jeselsohn collaborates with scholars based in United States, Italy and Australia. Rinath Jeselsohn's co-authors include Myles Brown, Rachel Schiff, Carmine De Angelis, Gilles Buchwalter, Charlotte Kuperwasser, Philip W. Hinds, Miaofen G. Hu, Nelson E. Brown, Noa Ben-Baruch and Keren Merenbakh-Lamin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Rinath Jeselsohn

68 papers receiving 2.1k citations

Hit Papers

ESR1 mutations—a mechanis... 2015 2026 2018 2022 2015 2022 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
    2015 454 citations Rinath Jeselsohn, Carmine De Angelis et al. profile →
  2. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer
    2022 147 citations Nabihah Tayob, Rinath Jeselsohn et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rinath Jeselsohn United States 23 1.1k 953 814 743 583 74 2.1k
Weiyi Toy United States 13 796 0.7× 1.0k 1.1× 605 0.7× 606 0.8× 656 1.1× 24 1.9k
Luca Malorni Italy 25 1.5k 1.4× 800 0.8× 1.1k 1.3× 867 1.2× 341 0.6× 78 2.3k
Charles Morris United Kingdom 12 1.8k 1.6× 695 0.7× 1.2k 1.4× 527 0.7× 1.1k 1.9× 21 2.7k
Jianzhong Shou China 17 856 0.8× 978 1.0× 426 0.5× 495 0.7× 508 0.9× 61 1.9k
Kristen E. Mengwasser United States 7 1.1k 1.0× 1.5k 1.6× 1.1k 1.3× 523 0.7× 152 0.3× 8 2.4k
Jiang Shou United States 15 1.3k 1.2× 1.4k 1.4× 352 0.4× 524 0.7× 947 1.6× 20 2.4k
L. Rhoda Molife United Kingdom 25 1.3k 1.2× 1.3k 1.4× 1.5k 1.9× 680 0.9× 245 0.4× 73 3.0k
Ariella B. Hanker United States 15 759 0.7× 942 1.0× 445 0.5× 453 0.6× 157 0.3× 41 1.6k
Ilenia Migliaccio Italy 23 1.2k 1.1× 828 0.9× 828 1.0× 583 0.8× 233 0.4× 64 2.1k
Sofia K. Gruvberger-Saal Sweden 20 1.3k 1.2× 1.3k 1.4× 442 0.5× 1.0k 1.4× 357 0.6× 28 2.4k

Countries citing papers authored by Rinath Jeselsohn

Since Specialization
Citations

This map shows the geographic impact of Rinath Jeselsohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rinath Jeselsohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rinath Jeselsohn more than expected).

Fields of papers citing papers by Rinath Jeselsohn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rinath Jeselsohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rinath Jeselsohn. The network helps show where Rinath Jeselsohn may publish in the future.

Co-authorship network of co-authors of Rinath Jeselsohn

This figure shows the co-authorship network connecting the top 25 collaborators of Rinath Jeselsohn. A scholar is included among the top collaborators of Rinath Jeselsohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rinath Jeselsohn. Rinath Jeselsohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Olsen, Sarah Naomi, Charlie Hatton, Zhengtao Chu, et al.. (2025). Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer. Cell Reports Medicine. 6(7). 102192–102192. 1 indexed citations
3.
Nardone, Agostina, Damien Friel, Francisco Hermida‐Prado, et al.. (2025). Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor–positive breast cancer. JCI Insight. 10(12). 1 indexed citations
4.
Goel, Shom, Bojana Jovanović, Melissa E. Hughes, et al.. (2025). A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research. 31(8). 1427–1436. 3 indexed citations
5.
6.
Goldberg, Jonathan, Jennifer L. Guerriero, Anne V. Philips, et al.. (2024). Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor–positive Breast Cancer. Cancer Research Communications. 4(2). 496–504. 7 indexed citations
7.
Jeselsohn, Rinath, Jingxin Fu, Reshma Mahtani, et al.. (2024). Abstract PS12-02: Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2- Metastatic Breast Cancer. Cancer Research. 84(9_Supplement). PS12–2. 1 indexed citations
8.
Gertz, Jason, et al.. (2024). Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies. Endocrinology. 165(6). 9 indexed citations
9.
Grinshpun, Albert, Wen Ma, Giorgio Gaglia, et al.. (2024). Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer. npj Breast Cancer. 10(1). 42–42. 3 indexed citations
10.
Stamatiades, George Alexiades, Yanan Kuang, Cloud P. Paweletz, et al.. (2024). Somatic Activating ESR1 Mutation in an Aggressive Prolactinoma. The Journal of Clinical Endocrinology & Metabolism. 110(4). 1166–1176. 4 indexed citations
11.
Stein, Shayna, Agostina Nardone, Weihan Liu, et al.. (2023). Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer. Cancer Research Communications. 3(11). 2331–2344. 5 indexed citations
12.
Solozobova, Valeria, Nicole Jung, Victor Gourain, et al.. (2023). Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy. Cancer Research Communications. 3(7). 1378–1396. 4 indexed citations
13.
Gaglia, Giorgio, Sheheryar Kabraji, Yang Dai, et al.. (2022). Temporal and spatial topography of cell proliferation in cancer. Nature Cell Biology. 24(3). 316–326. 31 indexed citations
14.
Qiu, Xintao, Avery Feit, Ariel Feiglin, et al.. (2021). CoBRA: Containerized Bioinformatics Workflow for Reproducible ChIP/ATAC-Seq Analysis. Genomics Proteomics & Bioinformatics. 19(4). 652–661. 16 indexed citations
15.
Park, Sunghee, Rachid Safi, Sandeep Artham, et al.. (2020). The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. Molecular Cancer Therapeutics. 19(7). 1395–1405. 27 indexed citations
16.
Dhimolea, Eugen, Ricardo De Matos Simoes, Xiang Weng, et al.. (2020). Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment. Cancer Research. 81(2). 371–383. 12 indexed citations
17.
Wu, Yanming, Zhao Zhang, Cecilia J. Proietti, et al.. (2017). Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2–ERα–GREB1 Transcriptional Axis. Cancer Research. 78(3). 671–684. 80 indexed citations
18.
Malorni, Luca, Mario Giuliano, Ilenia Migliaccio, et al.. (2016). Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Molecular Cancer Research. 14(5). 470–481. 31 indexed citations
19.
Jeselsohn, Rinath, William T. Barry, Ilenia Migliaccio, et al.. (2016). TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research. 22(23). 5755–5764. 20 indexed citations
20.
Brown, Nelson E., Rinath Jeselsohn, Teeru Bihani, et al.. (2012). Cyclin D1 Activity Regulates Autophagy and Senescence in the Mammary Epithelium. Cancer Research. 72(24). 6477–6489. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Weiyi Toy Breakdown of academic impact, for papers by Luca Malorni Breakdown of academic impact, for papers by Charles Morris Breakdown of academic impact, for papers by Jianzhong Shou Breakdown of academic impact, for papers by Kristen E. Mengwasser Breakdown of academic impact, for papers by Jiang Shou Breakdown of academic impact, for papers by L. Rhoda Molife Breakdown of academic impact, for papers by Ariella B. Hanker Breakdown of academic impact, for papers by Ilenia Migliaccio Breakdown of academic impact, for papers by Sofia K. Gruvberger-Saal
Rankless by CCL
2026